RYLAZE
Google image searchProduct monograph
Active ingredient
crisantaspase, 10 MG/0.5 ML
DIN: 02530406
Dosage form(s): SOLUTION
Route(s) of administration: INTRAMUSCULAR
Description: SINGLE-DOSE VIAL, RECOMBINANT
Schedule: Prescription / Schedule D
Company: JAZZ PHARMACEUTICALS IRELAND LIMITED
Date: 03-MAY-2023
ATC:
- L01 — ANTINEOPLASTIC AGENTS (ATC, ATC/DDD, )
- L01X — OTHER ANTINEOPLASTIC AGENTS (ATC, ATC/DDD)
- L01XX — Other antineoplastic agents (ATC, ATC/DDD)
- L01XX02 — ASPARAGINASE (ATC/DDD)
Reference brand drug: Erwinase, Kidrolase
